Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 5
2006 1
2007 2
2008 2
2010 1
2012 2
2013 2
2014 2
2015 8
2016 3
2017 2
2018 6
2019 12
2020 18
2021 21
2022 14
2023 14
2024 13
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, Warusavitarne J, Buskens CJ, van Bodegraven AA, Brink MA, Consten ECJ, van Wagensveld BA, Rijk MCM, Crolla RMPH, Noomen CG, Houdijk APJ, Mallant RC, Boom M, Marsman WA, Stockmann HB, Mol B, de Groof AJ, Stokkers PC, D'Haens GR, Bemelman WA; LIR!C study group. Ponsioen CY, et al. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):785-792. doi: 10.1016/S2468-1253(17)30248-0. Epub 2017 Aug 31. Lancet Gastroenterol Hepatol. 2017. PMID: 28838644 Clinical Trial.
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
Stevens TW, Haasnoot ML, D'Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Mol B, Stokkers PCF, Bemelman WA, Ponsioen CY; LIR!C study group. Stevens TW, et al. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):900-907. doi: 10.1016/S2468-1253(20)30117-5. Epub 2020 Jun 30. Lancet Gastroenterol Hepatol. 2020. PMID: 32619413 Clinical Trial.
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
D'Haens G, Taxonera C, Lopez-Sanroman A, Nos P, Danese S, Armuzzi A, Roblin X, Peyrin-Biroulet L, West R, Mares WGN, Duijvestein M, Gecse KB, Feagan BG, Zou G, Hulshoff MS, Mookhoek A, Oldenburg L, Clasquin E, Bouhnik Y, Laharie D. D'Haens G, et al. Among authors: west r. Lancet Gastroenterol Hepatol. 2025 Jan;10(1):26-33. doi: 10.1016/S2468-1253(24)00317-0. Epub 2024 Nov 18. Lancet Gastroenterol Hepatol. 2025. PMID: 39571587 Clinical Trial.
Voriconazole pharmacogenetics - Authors' reply.
Maertens JA, Waskin HA, West RM, Shaw PM. Maertens JA, et al. Among authors: west rm. Lancet. 2021 Aug 14;398(10300):578-579. doi: 10.1016/S0140-6736(21)00874-6. Lancet. 2021. PMID: 34391493 No abstract available.
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group and the Dutch Initiative on Crohn and Colitis. van Linschoten RCA, et al. Among authors: west rl. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):343-355. doi: 10.1016/S2468-1253(22)00434-4. Epub 2023 Jan 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36736339 Clinical Trial.
Interobserver agreement of current and new proposed endoscopic scores for postoperative recurrence in Crohn's disease.
Bak MTJ, Hammoudi N, Allez M, Silverberg MS, Schellekens IM, Erler NS, Dijkstra G, Romberg-Camps M, de Boer NKH, Jansen SV, van der Marel S, Horjus CS, Visschedijk MC, Goetgebuer RL, van Dop WA, Hoekstra J, Bodelier AGL, Molendijk I, Derikx LAAP, van Schaik FDM, West RL, Duijvestein M, Janneke van der Woude C, van Ruler O, de Vries AC; Dutch Initiative on Crohn and Colitis and the RAP-CD study group. Bak MTJ, et al. Among authors: west rl. Gastrointest Endosc. 2024 Oct;100(4):703-709.e4. doi: 10.1016/j.gie.2024.03.011. Epub 2024 Mar 8. Gastrointest Endosc. 2024. PMID: 38462057 Free article.
Nanomaterials for Neurology: State-of-the-Art.
Veloz-Castillo MF, West RM, Cordero-Arreola J, Arias-Carrión O, Méndez-Rojas MA. Veloz-Castillo MF, et al. Among authors: west rm. CNS Neurol Disord Drug Targets. 2016;15(10):1306-1324. doi: 10.2174/1871527315666160801144637. CNS Neurol Disord Drug Targets. 2016. PMID: 27488421
Predicting mucosal inflammation in IBD patients using patient-reported symptom scores and a faecal calprotectin home test: protocol for a multicentre prospective validation study.
Janssen L, van Linschoten RCA, West RL, Gilissen LPL, Romberg-Camps M, Brandts L, Mujagic Z, Römkens TE, Pierik M. Janssen L, et al. Among authors: west rl. BMJ Open. 2024 Oct 7;14(10):e076290. doi: 10.1136/bmjopen-2023-076290. BMJ Open. 2024. PMID: 39375184 Free PMC article.
The Role of Innate Immune System Receptors in Epilepsy Research.
Cordero-Arreola J, West RM, Mendoza-Torreblanca J, Mendez-Hernandez E, Salas-Pacheco J, Menendez-Gonzalez M, Freire RC, Machado S, Murillo-Rodriguez E, Nardi AE, Arias-Carrion O. Cordero-Arreola J, et al. Among authors: west rm. CNS Neurol Disord Drug Targets. 2017;16(7):749-762. doi: 10.2174/1871527316666170725145549. CNS Neurol Disord Drug Targets. 2017. PMID: 28745241 Review.
111 results